Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for CRISPR Therapeutics AG (CRSP : NSDQ)

• Company Description    CRISPR Therapeutics AG is a leading gene editing company focused on developing CRISPR/Cas9-based therapeutics. The company is rapidly leveraging its CRISPR/Cas9 gene-editing platform to make therapies for the treatment of hemoglobinopathies, cancer, diabetes and other diseases. Number of Employees: 0

• Price / Volume Information    Yesterday's Closing Price: $55.79 Daily Weekly Monthly 20 Day Moving Average: 1,366,760 shares Shares Outstanding: 96.69 (millions) Market Capitalization: $5,394.48 (millions) Beta: 1.76 52 Week High: $78.48 52 Week Low: $44.12 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 4.26% 4.73% 12 Week 6.04% 3.79% Year To Date 6.39% -5.65%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL BAARERSTRASSE 14 - ZUG,V8 CH-6300 CHE ph: 41-41-561-3277 fax: - ir@crisprtx.com http://www.crisprtx.com

• General Corporate Information    Officers Samarth Kulkarni - Chief Executive Officer; Chairman and Director Raju Prasad - Chief Financial Officer Ali Behbahani - Director Maria Fardis - Director H. Edward Fleming, Jr. - Director Peer Information CRISPR Therapeutics AG (CORR.) CRISPR Therapeutics AG (RSPI) CRISPR Therapeutics AG (CGXP) CRISPR Therapeutics AG (BGEN) CRISPR Therapeutics AG (GTBP) CRISPR Therapeutics AG (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: H17182108 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/26 Next Expected EPS Date: 11/09/26 Share - Related Items Shares Outstanding: 96.69 Most Recent Split Date: (:1) Beta: 1.76 Market Capitalization: $5,394.48 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-1.06 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-4.47 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 11.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: 30.10% Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/09/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 3.08 Price/Cash Flow: - Price / Sales: 402.82 EPS Growth vs. Year Ago Period: 27.13% vs. Previous Quarter: 26.56% Sales Growth vs. Year Ago Period: 1,041.37% vs. Previous Quarter: 598.29% ROE 06/30/26 - -24.39 03/31/26 - -25.66 12/31/25 - -26.31 ROA 06/30/26 - -18.25 03/31/26 - -20.39 12/31/25 - -22.30 Current Ratio 06/30/26 - 17.85 03/31/26 - 17.97 12/31/25 - 13.32 Quick Ratio 06/30/26 - 17.85 03/31/26 - 17.96 12/31/25 - 13.32 Operating Margin 06/30/26 - -3,368.72 03/31/26 - -11,510.63 12/31/25 - -13,827.52 Net Margin 06/30/26 - -3,368.72 03/31/26 - -13,856.54 12/31/25 - -16,569.77 Pre-Tax Margin 06/30/26 - -3,346.08 03/31/26 - -13,774.56 12/31/25 - -16,466.24 Book Value 06/30/26 - 18.11 03/31/26 - 18.82 12/31/25 - 20.17 Inventory Turnover 06/30/26 - - 03/31/26 - - 12/31/25 - - Debt-to-Equity 06/30/26 - 0.34 03/31/26 - 0.32 12/31/25 - 0.00 Debt-to-Capital 06/30/26 - 25.13 03/31/26 - 24.39 12/31/25 - 0.00

Powered by Zacks Investment Research ©